Payment overview · 2025
General Payments
$618.86
25 reported records · 8 companies
Healthcare provider profile · identity verified
John Ervin Dickson, M.D.
Allopathic & Osteopathic Physicians|General Practice · SAN ANTONIO, TX · NPI 1154467116
Verified facts
What the public records show
CMS Open Payments records show John Ervin Dickson, M.D. received $618.86 in general payments during 2025 across 25 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 52.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $325.71 | 52.6% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.57 | 12.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.39 | 9.8% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $48.48 | 7.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.91 | 5.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.91 | 4.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.38 | 4.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.51 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $618.86 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $325.71 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.57 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.39 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $48.48 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 584 | 176 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 539 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 139 |
| Losartan Potassium | Losartan Potassium | 464 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 135 |
| Omeprazole | Omeprazole | 311 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 77 |
| Metformin Hcl Er | Metformin Hcl | 222 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 61 |
| Lisinopril | Lisinopril | 195 | 57 |
| Montelukast Sodium | Montelukast Sodium | 183 | 61 |
| Ozempic | Semaglutide | 167 | 32 |
| Finasteride | Finasteride | 166 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 46 |
| Simvastatin | Simvastatin | 152 | 47 |
| Sertraline Hcl | Sertraline Hcl | 148 | 52 |
| Alprazolam | Alprazolam | 143 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 25 |
| Jardiance | Empagliflozin | 138 | 37 |
| Trazodone Hcl | Trazodone Hcl | 133 | 47 |
| Ezetimibe | Ezetimibe | 126 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 32 |
| Gabapentin | Gabapentin | 118 | 39 |
| Eliquis | Apixaban | 116 | 29 |
| Metformin Hcl | Metformin Hcl | 111 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 35 |
| Telmisartan | Telmisartan | 100 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 28 |
| Carvedilol | Carvedilol | 89 | 28 |
| Irbesartan | Irbesartan | 85 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 82 | 13 |
| Tramadol Hcl | Tramadol Hcl | 81 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 26 |
| Chlorthalidone | Chlorthalidone | 72 | 25 |
| Clonazepam | Clonazepam | 70 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 22 |
| Valsartan | Valsartan | 63 | 18 |
| Allopurinol | Allopurinol | 59 | 17 |
| Potassium Chloride | Potassium Chloride | 54 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 18 |
| Ibuprofen | Ibuprofen | 53 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 17 |
| Lorazepam | Lorazepam | 49 | 20 |
| Spironolactone | Spironolactone | 48 | 17 |
| Estradiol | Estradiol | 46 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 15 |
| Fenofibrate | Fenofibrate | 44 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 14 |
| Furosemide | Furosemide | 42 | 15 |
| Meloxicam | Meloxicam | 41 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 13 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Atenolol | Atenolol | 40 | 13 |
| Diazepam | Diazepam | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Pregabalin | Pregabalin | 39 | 12 |
| Naproxen | Naproxen | 37 | 12 |
| Donepezil Hcl | Donepezil Hcl | 36 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 22 |
| Lovastatin | Lovastatin | 34 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 12 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Baclofen | Baclofen | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Euthyrox | Levothyroxine Sodium | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Zaleplon | Zaleplon | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $618.86 · 25 records | Bayer Healthcare Pharmaceuticals Inc. | Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, IBSRELA, INSPIRE, JARDIANCE, Kerendia, NURTEC ODT, QULIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error